Immunic, Inc. (NASDAQ:IMUX) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Immunic, Inc. (IMUX)
Company Research
Source: Yahoo! Finance
Reported EPS is $-0.48, expectations were $-0.51. IMUX isn't one of the 30 most popular stocks among hedge funds at the end of the third quarter ( see the details here Jessica Breu: Good morning to everybody on the line. I would like to welcome you to Immunic's Fourth Quarter and Year End 2023 Earnings Call. My name is Jessica Breu, Vice President, Investor Relations and Communications at Immunic. I will also be the moderator today. Speaking on the call are Dr. Daniel Vitt, our Chief Executive Officer and President; as well as Glenn Whaley, our Chief Financial Officer. Please note that all participants will be in listen-only mode, and this event is being recorded. After today's presentation, there will be an opportunity to ask questions. [Operator Instructions] Before we begin, I would like to remind you that this presentation may contain forward-looking statements. Such statements can be identified by words such as may, will, expect, anticipate, estimate or words with a similar mea
Show less
Read more
Impact Snapshot
Event Time:
IMUX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMUX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMUX alerts
High impacting Immunic, Inc. news events
Weekly update
A roundup of the hottest topics
IMUX
News
- Immunic Phase 2 EMPhASIS trial data highlighted in peer-reviewed neurology journal [Yahoo! Finance]Yahoo! Finance
- Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update [Yahoo! Finance]Yahoo! Finance
- Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate UpdatePR Newswire
- Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & Neuroinflammation [Yahoo! Finance]Yahoo! Finance
- Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & NeuroinflammationPR Newswire
IMUX
Earnings
- 11/14/23 - Beat
IMUX
Sec Filings
- 5/1/24 - Form EFFECT
- 4/30/24 - Form 424B3
- 4/23/24 - Form DEF
- IMUX's page on the SEC website